Allocation of Casirivimab/Imdevimab by Jurisdiction

Casirivimab/imdevimab is being allocated by the federal government to states, territories, and federal entities on a weekly basis. Casirivimab/Imdevimab Allocation Table is current through February 2, 2021.

Distribution Weeks:

Distribution Cycle 1 - Week 1: November 24 - December 1, 2020
Distribution Cycle 2 - Week 2: December 2 -8, 2020
Distribution Cycle 3 - Week 3: December 9-15, 2020
Distribution Cycle 4 - Week 4: December 16-22, 2020
Distribution Cycle 5 - Weeks 5-6: December 23, 2020 - January 5, 2021
Distribution Cycle 6 - Weeks 7-8: January 6 - 19, 2021
Distribution Cycle 7 - Weeks 9-10: January 19 - February 2, 2021

States / Territories / Federal Entities	Week 1 Phase 1 (patient courses)	Week 2 Phase 1 (patient courses)	Week 3 Phase 1 (patient courses)	Week 4 Phase 1 (patient courses)	Week 5-6 Phase 2 (patient courses)	Week 7-8 Phase 2 (patient courses)	Week 9-10 Phase 2 (patient courses)	Total Patient Courses Allocated
Alabama	456	330	180	180	508	170	190	2,014
Alaska	96	80	30	30	40	20	20	316
American Samoa	0	0	0	0	0	0	10	10
Arizona	720	550	320	400	710	340	510	3,550
Arkansas	384	270	130	130	250	120	160	1,444
Bureau of Prisons	0	0	0	0	192	72	72	456
California	2,328	2,160	1,240	1,380	4,120	1,620	2,460	15,308
Colorado	960	640	250	250	100	110	140	2,450
Commonwealth of the Northern Mariana Islands	0	0	0	0	10	0	0	10
Connecticut	384	250	140	140	240	90	160	1,404
Delaware	96	80	50	50	90	30	50	446
Department of Defense	216	400	1,000	1,000	300	100	100	3,116
Departmentof Health and Human Services	0	0	0	0	0	0	0	0
Department of State	0	0	0	0	0	0	0	0
District of Columbia	48	40	20	20	40	20	20	208
Federated States of Micronesia	0	0	0	0	0	0	0	0
Florida	1,608	1,220	560	560	1,210	630	870	6,658
Georgia	744	520	290	340	720	410	550	3,574
Guam	0	10	10	10	10	10	0	50
Hawaii	24	20	10	10	20	10	20	114
Idaho	240	170	80	80	120	40	60	790
Illinois	2,280	1,330	550	550	800	270	380	6,160
Indiana	1,248	820	370	370	600	570	250	4,228
Indian Health Service	216	400	1,000	1,000	600	600	600	4,416
Iowa	744	370	130	130	160	60	90	1,684
Kansas	576	360	150	150	250	100	140	1,726
Kentucky	840	590	270	270	450	190	220	2,830
Louisiana	456	280	160	160	1,630	902	580	4,168
Maine	48	30	20	20	40	20	50	228
Maryland	528	380	180	180	290	130	190	1,878
Massachusetts	504	340	230	240	450	200	0	1,964
Michigan	1,512	1,110	420	420	530	160	190	4,342
Minnesota	1,152	750	260	260	270	80	100	2,872
Mississippi	312	240	120	120	240	110	130	1,272
Missouri	1,032	610	240	240	390	150	150	2,812
Montana	264	150	60	60	70	20	40	664
National Institute of Health	0	0	0	0	0	0	0	0
Nebraska	456	260	100	100	120	40	70	1,146
Nevada	432	340	150	150	280	100	130	1,582
New Hampshire	72	60	40	50	80	40	50	392
New Jersey	864	680	320	320	570	220	492	3,466
New Mexico	432	240	100	100	150	60	80	1,162
New York	1,224	1,100	580	580	1,180	600	980	6,244
North Carolina	696	530	270	300	782	320	480	3,378
North Dakota	240	120	40	40	40	20	20	520
Ohio	1,680	1,320	560	640	990	350	470	6,010
Oklahoma	696	520	210	210	400	546	230	2,812
Oregon	216	180	80	80	130	50	80	816
Palau	0	0	0	0	0	0	0	0
Pennsylvania	1,368	1,130	570	590	1,060	360	440	5,518
Puerto Rico	0	100	40	40	80	30	50	340
Republic of Marshall Islands	0	0	0	0	0	0	0	0
Rhode Island	168	110	60	60	90	40	70	598
South Carolina	312	220	140	150	310	242	270	1,644
South Dakota	240	140	50	50	60	20	30	590
Tennessee	840	630	280	370	830	270	300	3,520
Texas	2,784	1,850	830	1,850	2,116	1,216	1,480	12,126
U.S. Virgin Islands	0	10	10	10	10	10	10	60
Utah	552	290	140	140	220	100	170	1,612
Vermont	24	10	10	10	10	10	20	94
Veterans Health Administration	216	400	1,000	1,000	300	0	100	3,016
Virginia	456	360	170	200	380	190	370	2,126
Washington	312	320	140	140	180	100	0	1,192
West Virginia	192	150	70	70	140	270	80	972
Wisconsin	1,440	790	290	290	430	130	180	3,550
Wyoming	144	80	30	30	40	20	30	374
All Jurisdictions (patient courses)	36,072	26,440	14,870	16,320	26,428	12,708	15,184	148,022

Current Total Monoclonal Antibody Therapeutics Allocated and Delivered

Therapeutic	Total Allocation (patient courses)	Total Delivered (patient courses)
Bamlanivimab (through March 2, 2021)	798,591	664,691
Casirivimab/imdevimab (through February 2, 2021)	148,022	96,923
All Monoclonal Antibody Therapeutics	946,613	761,614

Allocation Phases

Phase 1: allocation to hospitals and hospital-affiliated locations
Phase 2: allocation expanded to additional outpatients facilities

HHS-ASPR Resources

This page last reviewed: February 17, 2021